Stem definition | Drug id | CAS RN |
---|---|---|
4746 | 19171-19-8 |
Dose | Unit | Route |
---|---|---|
3 | mg | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 8, 2013 | FDA | CELGENE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Plasma cell myeloma | 5858.20 | 20.56 | 2034 | 43988 | 42444 | 46597596 |
Death | 1322.35 | 20.56 | 1632 | 44390 | 333916 | 46306124 |
Pneumonia | 1126.29 | 20.56 | 1600 | 44422 | 374720 | 46265320 |
Full blood count decreased | 1091.70 | 20.56 | 501 | 45521 | 21710 | 46618330 |
White blood cell count decreased | 847.14 | 20.56 | 774 | 45248 | 111457 | 46528583 |
Neuropathy peripheral | 586.11 | 20.56 | 575 | 45447 | 90318 | 46549722 |
Laboratory test abnormal | 584.86 | 20.56 | 332 | 45690 | 22515 | 46617525 |
Neutropenia | 441.14 | 20.56 | 620 | 45402 | 142584 | 46497456 |
Adverse drug reaction | 343.61 | 20.56 | 311 | 45711 | 44051 | 46595989 |
Unevaluable event | 308.15 | 20.56 | 298 | 45724 | 45877 | 46594163 |
Thrombosis | 283.98 | 20.56 | 312 | 45710 | 55757 | 46584283 |
Platelet count decreased | 281.13 | 20.56 | 415 | 45607 | 99609 | 46540431 |
Neutrophil count decreased | 279.91 | 20.56 | 275 | 45747 | 43151 | 46596889 |
Fatigue | 255.10 | 20.56 | 1227 | 44795 | 607470 | 46032570 |
Plasma cell myeloma recurrent | 254.31 | 20.56 | 94 | 45928 | 2313 | 46637727 |
Influenza | 234.55 | 20.56 | 359 | 45663 | 88911 | 46551129 |
Rheumatoid arthritis | 217.07 | 20.56 | 4 | 46018 | 240211 | 46399829 |
Plasmacytoma | 198.17 | 20.56 | 79 | 45943 | 2398 | 46637642 |
Constipation | 197.85 | 20.56 | 491 | 45531 | 173606 | 46466434 |
Nasopharyngitis | 191.76 | 20.56 | 450 | 45572 | 153548 | 46486492 |
Condition aggravated | 182.69 | 20.56 | 16 | 46006 | 245036 | 46395004 |
Human chorionic gonadotropin increased | 148.58 | 20.56 | 53 | 45969 | 1174 | 46638866 |
Drug interaction | 139.21 | 20.56 | 18 | 46004 | 203076 | 46436964 |
Drug ineffective | 127.04 | 20.56 | 303 | 45719 | 677535 | 45962505 |
Bronchitis | 112.98 | 20.56 | 292 | 45730 | 105687 | 46534353 |
Infection | 112.75 | 20.56 | 338 | 45684 | 133254 | 46506786 |
Drug hypersensitivity | 109.14 | 20.56 | 52 | 45970 | 243773 | 46396267 |
Peripheral swelling | 98.58 | 20.56 | 361 | 45661 | 157710 | 46482330 |
Full blood count increased | 90.65 | 20.56 | 34 | 45988 | 872 | 46639168 |
Muscle spasms | 90.50 | 20.56 | 297 | 45725 | 122816 | 46517224 |
Product dose omission issue | 88.08 | 20.56 | 364 | 45658 | 168156 | 46471884 |
COVID-19 | 84.77 | 20.56 | 98 | 45924 | 18477 | 46621563 |
Cytopenia | 83.86 | 20.56 | 66 | 45956 | 7702 | 46632338 |
Asthenia | 83.39 | 20.56 | 558 | 45464 | 310517 | 46329523 |
Renal disorder | 81.03 | 20.56 | 115 | 45907 | 26571 | 46613469 |
Light chain analysis increased | 78.03 | 20.56 | 32 | 45990 | 1046 | 46638994 |
Arthralgia | 76.21 | 20.56 | 153 | 45869 | 364450 | 46275590 |
Tremor | 76.21 | 20.56 | 269 | 45753 | 115370 | 46524670 |
Abdominal pain | 75.94 | 20.56 | 69 | 45953 | 229962 | 46410078 |
Cardiac disorder | 73.81 | 20.56 | 145 | 45877 | 43713 | 46596327 |
Anaemia | 68.58 | 20.56 | 459 | 45563 | 255320 | 46384720 |
Overdose | 67.54 | 20.56 | 10 | 46012 | 101969 | 46538071 |
Multiple allergies | 65.65 | 20.56 | 56 | 45966 | 7315 | 46632725 |
Vomiting | 65.04 | 20.56 | 229 | 45793 | 452565 | 46187475 |
Red blood cell count decreased | 62.50 | 20.56 | 114 | 45908 | 32509 | 46607531 |
Headache | 62.18 | 20.56 | 252 | 45770 | 478100 | 46161940 |
Psoriasis | 61.69 | 20.56 | 4 | 46018 | 78600 | 46561440 |
Hip fracture | 58.93 | 20.56 | 99 | 45923 | 26457 | 46613583 |
Urinary tract infection | 56.45 | 20.56 | 391 | 45631 | 219875 | 46420165 |
Therapeutic product effect incomplete | 55.78 | 20.56 | 6 | 46016 | 78147 | 46561893 |
Blood test abnormal | 55.24 | 20.56 | 57 | 45965 | 9463 | 46630577 |
Thrombocytopenia | 54.39 | 20.56 | 258 | 45764 | 126323 | 46513717 |
Back pain | 53.31 | 20.56 | 372 | 45650 | 209667 | 46430373 |
Product use in unapproved indication | 53.01 | 20.56 | 12 | 46010 | 90261 | 46549779 |
Product use issue | 52.81 | 20.56 | 14 | 46008 | 94630 | 46545410 |
Plasma cell leukaemia | 52.60 | 20.56 | 25 | 45997 | 1168 | 46638872 |
Atrial fibrillation | 51.89 | 20.56 | 221 | 45801 | 103369 | 46536671 |
Crystal nephropathy | 51.37 | 20.56 | 22 | 46000 | 803 | 46639237 |
Immune system disorder | 50.28 | 20.56 | 50 | 45972 | 7945 | 46632095 |
Cataract | 48.19 | 20.56 | 125 | 45897 | 45290 | 46594750 |
Sepsis | 47.10 | 20.56 | 261 | 45761 | 135753 | 46504287 |
Hyponatraemia | 46.21 | 20.56 | 21 | 46001 | 101311 | 46538729 |
Hypercalcaemia | 46.08 | 20.56 | 78 | 45944 | 20968 | 46619072 |
Haemoglobin decreased | 45.70 | 20.56 | 249 | 45773 | 128700 | 46511340 |
Malaise | 45.67 | 20.56 | 513 | 45509 | 330719 | 46309321 |
Rash | 44.65 | 20.56 | 542 | 45480 | 355970 | 46284070 |
Seizure | 42.88 | 20.56 | 35 | 45987 | 123019 | 46517021 |
Tooth disorder | 42.83 | 20.56 | 80 | 45942 | 23223 | 46616817 |
Dizziness | 42.82 | 20.56 | 518 | 45504 | 339896 | 46300144 |
Hypokalaemia | 42.11 | 20.56 | 17 | 46005 | 88007 | 46552033 |
Wrong technique in product usage process | 42.02 | 20.56 | 3 | 46019 | 54419 | 46585621 |
Anxiety | 41.77 | 20.56 | 72 | 45950 | 181885 | 46458155 |
Bone pain | 41.72 | 20.56 | 121 | 45901 | 46769 | 46593271 |
Respiratory syncytial virus infection | 41.57 | 20.56 | 36 | 45986 | 4799 | 46635241 |
Blood count abnormal | 41.47 | 20.56 | 68 | 45954 | 17810 | 46622230 |
Renal failure | 41.36 | 20.56 | 221 | 45801 | 113373 | 46526667 |
Fall | 41.05 | 20.56 | 500 | 45522 | 328597 | 46311443 |
Intentional product use issue | 40.50 | 20.56 | 3 | 46019 | 52777 | 46587263 |
Infusion related reaction | 40.23 | 20.56 | 25 | 45997 | 101183 | 46538857 |
Drug intolerance | 38.19 | 20.56 | 262 | 45760 | 146787 | 46493253 |
Alanine aminotransferase increased | 37.79 | 20.56 | 20 | 46002 | 88431 | 46551609 |
Coma | 35.80 | 20.56 | 7 | 46015 | 58342 | 46581698 |
Anaphylactic reaction | 35.64 | 20.56 | 5 | 46017 | 53107 | 46586933 |
Treatment failure | 35.63 | 20.56 | 24 | 45998 | 93063 | 46546977 |
Tachycardia | 35.12 | 20.56 | 28 | 45994 | 99594 | 46540446 |
Hospitalisation | 34.19 | 20.56 | 10 | 46012 | 63375 | 46576665 |
Deep vein thrombosis | 33.80 | 20.56 | 162 | 45860 | 79611 | 46560429 |
Pulmonary thrombosis | 33.68 | 20.56 | 39 | 45983 | 7363 | 46632677 |
Respiratory tract infection | 33.35 | 20.56 | 84 | 45938 | 29888 | 46610152 |
Aspartate aminotransferase increased | 33.32 | 20.56 | 18 | 46004 | 78682 | 46561358 |
Bone lesion | 33.17 | 20.56 | 32 | 45990 | 4899 | 46635141 |
Blood calcium increased | 32.90 | 20.56 | 39 | 45983 | 7548 | 46632492 |
Pain | 32.17 | 20.56 | 308 | 45714 | 476640 | 46163400 |
Electrocardiogram QT prolonged | 31.82 | 20.56 | 6 | 46016 | 51319 | 46588721 |
Back disorder | 31.67 | 20.56 | 42 | 45980 | 9099 | 46630941 |
Seasonal allergy | 31.31 | 20.56 | 51 | 45971 | 13283 | 46626757 |
Monoclonal immunoglobulin present | 30.89 | 20.56 | 15 | 46007 | 735 | 46639305 |
Pneumonia influenzal | 30.89 | 20.56 | 19 | 46003 | 1490 | 46638550 |
Diarrhoea | 29.71 | 20.56 | 741 | 45281 | 558861 | 46081179 |
Cardio-respiratory arrest | 29.56 | 20.56 | 11 | 46011 | 59858 | 46580182 |
Agitation | 29.42 | 20.56 | 9 | 46013 | 55406 | 46584634 |
Kidney infection | 28.83 | 20.56 | 56 | 45966 | 16733 | 46623307 |
Protein total increased | 28.68 | 20.56 | 22 | 46000 | 2471 | 46637569 |
Amyloidosis | 28.00 | 20.56 | 16 | 46006 | 1095 | 46638945 |
Pancytopenia | 27.95 | 20.56 | 161 | 45861 | 84897 | 46555143 |
Monoclonal immunoglobulin increased | 27.59 | 20.56 | 8 | 46014 | 88 | 46639952 |
Tooth infection | 27.51 | 20.56 | 46 | 45976 | 12240 | 46627800 |
SARS-CoV-2 test positive | 26.67 | 20.56 | 19 | 46003 | 1906 | 46638134 |
Off label use | 26.56 | 20.56 | 243 | 45779 | 379598 | 46260442 |
International normalised ratio increased | 26.02 | 20.56 | 7 | 46015 | 46876 | 46593164 |
Therapeutic product effect decreased | 25.78 | 20.56 | 26 | 45996 | 82575 | 46557465 |
Liver function test abnormal | 25.69 | 20.56 | 7 | 46015 | 46480 | 46593560 |
Ascites | 25.62 | 20.56 | 3 | 46019 | 36581 | 46603459 |
Suicidal ideation | 25.21 | 20.56 | 12 | 46010 | 56370 | 46583670 |
Memory impairment | 25.16 | 20.56 | 146 | 45876 | 77191 | 46562849 |
Ear infection | 25.08 | 20.56 | 64 | 45958 | 22949 | 46617091 |
Product quality issue | 24.77 | 20.56 | 3 | 46019 | 35645 | 46604395 |
Bradycardia | 24.17 | 20.56 | 18 | 46004 | 66280 | 46573760 |
Swelling face | 24.12 | 20.56 | 110 | 45912 | 52949 | 46587091 |
Osteoarthritis | 23.72 | 20.56 | 16 | 46006 | 62009 | 46578031 |
Localised infection | 23.70 | 20.56 | 64 | 45958 | 23737 | 46616303 |
Pseudomonas aeruginosa meningitis | 23.69 | 20.56 | 4 | 46018 | 0 | 46640040 |
Cystitis | 23.40 | 20.56 | 93 | 45929 | 42148 | 46597892 |
Cardiac amyloidosis | 23.36 | 20.56 | 11 | 46011 | 503 | 46639537 |
Lower limb fracture | 23.33 | 20.56 | 43 | 45979 | 12355 | 46627685 |
Dysphonia | 23.26 | 20.56 | 87 | 45935 | 38327 | 46601713 |
Hepatic enzyme increased | 23.04 | 20.56 | 28 | 45994 | 81759 | 46558281 |
Mobility decreased | 22.68 | 20.56 | 16 | 46006 | 60578 | 46579462 |
Peritonitis viral | 22.40 | 20.56 | 6 | 46016 | 48 | 46639992 |
Hypoglycaemia | 22.18 | 20.56 | 13 | 46009 | 54336 | 46585704 |
Nervousness | 22.06 | 20.56 | 70 | 45952 | 28405 | 46611635 |
Malignant neoplasm progression | 21.95 | 20.56 | 19 | 46003 | 64907 | 46575133 |
Loss of personal independence in daily activities | 21.53 | 20.56 | 15 | 46007 | 57168 | 46582872 |
Fibromyalgia | 21.09 | 20.56 | 5 | 46017 | 36458 | 46603582 |
JC virus CSF test positive | 20.85 | 20.56 | 5 | 46017 | 24 | 46640016 |
Inappropriate schedule of product administration | 20.82 | 20.56 | 20 | 46002 | 64993 | 46575047 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Plasma cell myeloma | 5844.74 | 19.58 | 2412 | 44335 | 51050 | 29854681 |
Death | 1520.98 | 19.58 | 2280 | 44467 | 355003 | 29550728 |
Pneumonia | 1399.02 | 19.58 | 2118 | 44629 | 332188 | 29573543 |
Full blood count decreased | 827.77 | 19.58 | 430 | 46317 | 15287 | 29890444 |
White blood cell count decreased | 662.28 | 19.58 | 732 | 46015 | 83215 | 29822516 |
Laboratory test abnormal | 637.11 | 19.58 | 375 | 46372 | 17067 | 29888664 |
Adverse drug reaction | 514.20 | 19.58 | 364 | 46383 | 22781 | 29882950 |
Fatigue | 481.86 | 19.58 | 1334 | 45413 | 319339 | 29586392 |
Neuropathy peripheral | 455.43 | 19.58 | 555 | 46192 | 69920 | 29835811 |
Influenza | 441.32 | 19.58 | 434 | 46313 | 42964 | 29862767 |
Unevaluable event | 376.59 | 19.58 | 346 | 46401 | 31439 | 29874292 |
Thrombosis | 349.17 | 19.58 | 378 | 46369 | 41853 | 29863878 |
Neutropenia | 342.16 | 19.58 | 671 | 46076 | 127869 | 29777862 |
Drug interaction | 254.99 | 19.58 | 14 | 46733 | 199554 | 29706177 |
Plasma cell myeloma recurrent | 243.73 | 19.58 | 115 | 46632 | 3299 | 29902432 |
Peripheral swelling | 189.63 | 19.58 | 341 | 46406 | 60733 | 29844998 |
Nasopharyngitis | 187.09 | 19.58 | 332 | 46415 | 58517 | 29847214 |
Platelet count decreased | 171.32 | 19.58 | 455 | 46292 | 105674 | 29800057 |
Plasmacytoma | 159.98 | 19.58 | 86 | 46661 | 3270 | 29902461 |
Infection | 153.54 | 19.58 | 361 | 46386 | 77713 | 29828018 |
Neutrophil count decreased | 144.62 | 19.58 | 247 | 46500 | 42207 | 29863524 |
Condition aggravated | 138.92 | 19.58 | 24 | 46723 | 137842 | 29767889 |
COVID-19 | 130.35 | 19.58 | 150 | 46597 | 17728 | 29888003 |
Cardiac disorder | 127.91 | 19.58 | 226 | 46521 | 39667 | 29866064 |
Constipation | 119.04 | 19.58 | 417 | 46330 | 112489 | 29793242 |
Renal disorder | 106.25 | 19.58 | 156 | 46591 | 23428 | 29882303 |
Drug intolerance | 105.30 | 19.58 | 224 | 46523 | 45067 | 29860664 |
Overdose | 104.25 | 19.58 | 7 | 46740 | 84330 | 29821401 |
Tooth disorder | 103.09 | 19.58 | 97 | 46650 | 9064 | 29896667 |
Back pain | 98.82 | 19.58 | 368 | 46379 | 102228 | 29803503 |
Plasma cell leukaemia | 91.02 | 19.58 | 39 | 46708 | 886 | 29904845 |
Deep vein thrombosis | 86.15 | 19.58 | 248 | 46499 | 60253 | 29845478 |
Asthenia | 84.27 | 19.58 | 612 | 46135 | 220678 | 29685053 |
Sepsis | 81.31 | 19.58 | 446 | 46301 | 145949 | 29759782 |
Rash | 76.67 | 19.58 | 537 | 46210 | 191352 | 29714379 |
Vomiting | 75.36 | 19.58 | 143 | 46604 | 219675 | 29686056 |
Rhabdomyolysis | 73.76 | 19.58 | 7 | 46740 | 63573 | 29842158 |
Aspartate aminotransferase increased | 73.53 | 19.58 | 7 | 46740 | 63415 | 29842316 |
Localised infection | 72.44 | 19.58 | 98 | 46649 | 13639 | 29892092 |
Full blood count increased | 72.19 | 19.58 | 32 | 46715 | 791 | 29904940 |
Light chain analysis increased | 71.69 | 19.58 | 34 | 46713 | 986 | 29904745 |
Muscle spasms | 71.28 | 19.58 | 243 | 46504 | 64595 | 29841136 |
Immune system disorder | 69.81 | 19.58 | 56 | 46691 | 4221 | 29901510 |
Hyponatraemia | 66.96 | 19.58 | 12 | 46735 | 67190 | 29838541 |
Product dose omission issue | 66.28 | 19.58 | 301 | 46446 | 91330 | 29814401 |
Alanine aminotransferase increased | 64.50 | 19.58 | 18 | 46729 | 74258 | 29831473 |
Blood count abnormal | 62.77 | 19.58 | 84 | 46663 | 11568 | 29894163 |
Acute kidney injury | 61.76 | 19.58 | 220 | 46527 | 273622 | 29632109 |
Abdominal pain | 61.19 | 19.58 | 73 | 46674 | 135581 | 29770150 |
Monoclonal immunoglobulin present | 59.97 | 19.58 | 29 | 46718 | 879 | 29904852 |
Atrial fibrillation | 59.68 | 19.58 | 329 | 46418 | 107795 | 29797936 |
Product use in unapproved indication | 58.40 | 19.58 | 21 | 46726 | 73672 | 29832059 |
Illness | 57.78 | 19.58 | 45 | 46702 | 3249 | 29902482 |
Agitation | 57.61 | 19.58 | 8 | 46739 | 54065 | 29851666 |
Malignant neoplasm progression | 54.94 | 19.58 | 22 | 46725 | 72265 | 29833466 |
Hypoglycaemia | 53.24 | 19.58 | 8 | 46739 | 50973 | 29854758 |
Toxicity to various agents | 52.53 | 19.58 | 125 | 46622 | 177058 | 29728673 |
Bronchitis | 52.42 | 19.58 | 157 | 46590 | 38968 | 29866763 |
Rheumatoid arthritis | 52.14 | 19.58 | 3 | 46744 | 41194 | 29864537 |
Blood test abnormal | 48.29 | 19.58 | 51 | 46696 | 5474 | 29900257 |
Hyperkalaemia | 47.13 | 19.58 | 22 | 46725 | 65988 | 29839743 |
Intentional product use issue | 45.08 | 19.58 | 3 | 46744 | 36437 | 29869294 |
Psoriasis | 43.64 | 19.58 | 7 | 46740 | 42499 | 29863232 |
Squamous cell carcinoma of skin | 43.62 | 19.58 | 62 | 46685 | 9033 | 29896698 |
Red blood cell count decreased | 43.50 | 19.58 | 114 | 46633 | 26207 | 29879524 |
Rib fracture | 43.25 | 19.58 | 74 | 46673 | 12646 | 29893085 |
Anxiety | 43.07 | 19.58 | 46 | 46701 | 89825 | 29815906 |
Cytopenia | 42.16 | 19.58 | 58 | 46689 | 8198 | 29897533 |
Fluid retention | 42.06 | 19.58 | 109 | 46638 | 24889 | 29880842 |
Hypokalaemia | 42.03 | 19.58 | 13 | 46734 | 50179 | 29855552 |
Headache | 41.99 | 19.58 | 145 | 46602 | 182161 | 29723570 |
Arthropathy | 41.91 | 19.58 | 97 | 46650 | 20630 | 29885101 |
Suicide attempt | 40.11 | 19.58 | 5 | 46742 | 36692 | 29869039 |
Back disorder | 39.87 | 19.58 | 48 | 46699 | 5946 | 29899785 |
Upper limb fracture | 39.56 | 19.58 | 40 | 46707 | 4080 | 29901651 |
Aggression | 38.06 | 19.58 | 6 | 46741 | 36901 | 29868830 |
Pulmonary thrombosis | 37.69 | 19.58 | 48 | 46699 | 6295 | 29899436 |
Wrong technique in product usage process | 37.29 | 19.58 | 3 | 46744 | 31152 | 29874579 |
International normalised ratio increased | 37.14 | 19.58 | 14 | 46733 | 47725 | 29858006 |
Hypotension | 37.05 | 19.58 | 174 | 46573 | 200391 | 29705340 |
Dyspnoea | 37.01 | 19.58 | 727 | 46020 | 332568 | 29573163 |
Nausea | 36.88 | 19.58 | 292 | 46455 | 296665 | 29609066 |
Ascites | 36.68 | 19.58 | 6 | 46741 | 35915 | 29869816 |
Electrocardiogram QT prolonged | 36.56 | 19.58 | 6 | 46741 | 35829 | 29869902 |
Respiratory tract infection | 36.35 | 19.58 | 77 | 46670 | 15429 | 29890302 |
Bone pain | 36.25 | 19.58 | 87 | 46660 | 18939 | 29886792 |
Seizure | 34.60 | 19.58 | 63 | 46684 | 98412 | 29807319 |
Hip fracture | 34.30 | 19.58 | 62 | 46685 | 11062 | 29894669 |
Jaundice | 34.14 | 19.58 | 5 | 46742 | 32481 | 29873250 |
Cardio-respiratory arrest | 33.91 | 19.58 | 24 | 46723 | 57282 | 29848449 |
Malaise | 33.52 | 19.58 | 403 | 46344 | 166559 | 29739172 |
Interstitial lung disease | 33.33 | 19.58 | 27 | 46720 | 60170 | 29845561 |
Coronary artery disease | 33.33 | 19.58 | 18 | 46729 | 49694 | 29856037 |
General physical health deterioration | 33.30 | 19.58 | 66 | 46681 | 99878 | 29805853 |
Protein total increased | 32.88 | 19.58 | 27 | 46720 | 2103 | 29903628 |
Hospitalisation | 32.84 | 19.58 | 14 | 46733 | 44305 | 29861426 |
Balance disorder | 32.66 | 19.58 | 128 | 46619 | 36365 | 29869366 |
Cataract | 32.49 | 19.58 | 91 | 46656 | 21744 | 29883987 |
Bone lesion | 31.56 | 19.58 | 29 | 46718 | 2628 | 29903103 |
Blood calcium increased | 31.54 | 19.58 | 31 | 46716 | 3056 | 29902675 |
Pancreatitis | 31.37 | 19.58 | 9 | 46738 | 36481 | 29869250 |
Coma | 31.23 | 19.58 | 12 | 46735 | 40437 | 29865294 |
Cardiac arrest | 31.21 | 19.58 | 61 | 46686 | 92789 | 29812942 |
Lower respiratory tract infection | 30.99 | 19.58 | 102 | 46645 | 26612 | 29879119 |
Drug reaction with eosinophilia and systemic symptoms | 30.85 | 19.58 | 4 | 46743 | 28484 | 29877247 |
Sinusitis | 30.69 | 19.58 | 118 | 46629 | 33227 | 29872504 |
Blood urea increased | 30.40 | 19.58 | 6 | 46741 | 31375 | 29874356 |
Hypercalcaemia | 30.40 | 19.58 | 63 | 46684 | 12432 | 29893299 |
Lactic acidosis | 30.17 | 19.58 | 6 | 46741 | 31207 | 29874524 |
Depressed level of consciousness | 30.08 | 19.58 | 11 | 46736 | 38211 | 29867520 |
Body height decreased | 30.05 | 19.58 | 33 | 46714 | 3701 | 29902030 |
Melaena | 29.80 | 19.58 | 7 | 46740 | 32430 | 29873301 |
Neutropenic sepsis | 29.51 | 19.58 | 59 | 46688 | 11350 | 29894381 |
Spinal fracture | 29.46 | 19.58 | 44 | 46703 | 6704 | 29899027 |
Fall | 29.40 | 19.58 | 422 | 46325 | 181450 | 29724281 |
White blood cell count abnormal | 29.37 | 19.58 | 28 | 46719 | 2658 | 29903073 |
Dysarthria | 29.18 | 19.58 | 6 | 46741 | 30484 | 29875247 |
Gastric disorder | 29.06 | 19.58 | 56 | 46691 | 10487 | 29895244 |
Injection site pain | 28.93 | 19.58 | 6 | 46741 | 30304 | 29875427 |
Gastrointestinal haemorrhage | 28.76 | 19.58 | 54 | 46693 | 83392 | 29822339 |
Inappropriate schedule of product administration | 28.72 | 19.58 | 13 | 46734 | 39715 | 29866016 |
SARS-CoV-2 test positive | 28.11 | 19.58 | 22 | 46725 | 1600 | 29904131 |
Blood bilirubin increased | 28.07 | 19.58 | 11 | 46736 | 36625 | 29869106 |
Tachycardia | 27.88 | 19.58 | 45 | 46702 | 73694 | 29832037 |
Gamma-glutamyltransferase increased | 27.63 | 19.58 | 6 | 46741 | 29344 | 29876387 |
Haematuria | 27.56 | 19.58 | 18 | 46729 | 44816 | 29860915 |
Musculoskeletal disorder | 27.49 | 19.58 | 36 | 46711 | 4853 | 29900878 |
Multiple allergies | 26.65 | 19.58 | 24 | 46723 | 2119 | 29903612 |
Metabolic acidosis | 25.94 | 19.58 | 13 | 46734 | 37448 | 29868283 |
Tooth infection | 25.80 | 19.58 | 36 | 46711 | 5155 | 29900576 |
Drug hypersensitivity | 25.73 | 19.58 | 42 | 46705 | 68477 | 29837254 |
Cerebral toxoplasmosis | 25.58 | 19.58 | 20 | 46727 | 1452 | 29904279 |
Respiratory arrest | 25.55 | 19.58 | 7 | 46740 | 29251 | 29876480 |
Angioedema | 25.25 | 19.58 | 11 | 46736 | 34373 | 29871358 |
Incorrect dose administered | 25.14 | 19.58 | 9 | 46738 | 31677 | 29874054 |
Blood immunoglobulin M increased | 24.79 | 19.58 | 10 | 46737 | 194 | 29905537 |
Bradycardia | 24.76 | 19.58 | 40 | 46707 | 65486 | 29840245 |
Acute myocardial infarction | 24.36 | 19.58 | 28 | 46719 | 52911 | 29852820 |
Arthralgia | 24.34 | 19.58 | 119 | 46628 | 135672 | 29770059 |
Hepatic function abnormal | 24.25 | 19.58 | 18 | 46729 | 41927 | 29863804 |
Respiration abnormal | 24.18 | 19.58 | 25 | 46722 | 2617 | 29903114 |
Agranulocytosis | 23.95 | 19.58 | 3 | 46744 | 21939 | 29883792 |
Ear infection | 23.89 | 19.58 | 42 | 46705 | 7332 | 29898399 |
Haematemesis | 23.39 | 19.58 | 6 | 46741 | 26197 | 29879534 |
Psychotic disorder | 23.34 | 19.58 | 3 | 46744 | 21512 | 29884219 |
Shock | 22.93 | 19.58 | 4 | 46743 | 22855 | 29882876 |
Blood pressure abnormal | 22.85 | 19.58 | 40 | 46707 | 6959 | 29898772 |
Pyrexia | 22.25 | 19.58 | 609 | 46138 | 293880 | 29611851 |
Seasonal allergy | 22.20 | 19.58 | 32 | 46715 | 4721 | 29901010 |
Blood creatinine increased | 22.15 | 19.58 | 71 | 46676 | 91304 | 29814427 |
Hypoacusis | 22.10 | 19.58 | 60 | 46687 | 14079 | 29891652 |
Blood lactate dehydrogenase increased | 22.05 | 19.58 | 3 | 46744 | 20598 | 29885133 |
Lower limb fracture | 21.99 | 19.58 | 28 | 46719 | 3671 | 29902060 |
White blood cell disorder | 21.73 | 19.58 | 17 | 46730 | 1235 | 29904496 |
Blood alkaline phosphatase increased | 21.69 | 19.58 | 11 | 46736 | 31476 | 29874255 |
Transaminases increased | 21.67 | 19.58 | 5 | 46742 | 23452 | 29882279 |
Encephalopathy | 21.09 | 19.58 | 12 | 46735 | 32193 | 29873538 |
Oxygen saturation decreased | 21.06 | 19.58 | 22 | 46725 | 43418 | 29862313 |
Sinus disorder | 20.88 | 19.58 | 36 | 46711 | 6189 | 29899542 |
Clostridium difficile infection | 20.81 | 19.58 | 63 | 46684 | 15720 | 29890011 |
Spinal disorder | 20.72 | 19.58 | 26 | 46721 | 3359 | 29902372 |
Mucosal inflammation | 20.49 | 19.58 | 11 | 46736 | 30483 | 29875248 |
White blood cell count increased | 20.49 | 19.58 | 19 | 46728 | 39654 | 29866077 |
Ventricular tachycardia | 20.30 | 19.58 | 6 | 46741 | 23856 | 29881875 |
Gastrointestinal infection | 20.06 | 19.58 | 27 | 46720 | 3738 | 29901993 |
Drug ineffective | 20.00 | 19.58 | 393 | 46354 | 339994 | 29565737 |
Hepatic enzyme increased | 19.85 | 19.58 | 14 | 46733 | 33480 | 29872251 |
Vertebral lesion | 19.84 | 19.58 | 8 | 46739 | 155 | 29905576 |
Source | Code | Description |
---|---|---|
ATC | L04AX06 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Other immunosuppressants |
MeSH PA | D020533 | Angiogenesis Inhibitors |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D006131 | Growth Inhibitors |
MeSH PA | D006133 | Growth Substances |
MeSH PA | D007155 | Immunologic Factors |
FDA EPC | N0000184014 | Thalidomide Analog |
CHEBI has role | CHEBI:35610 | cytostatic |
CHEBI has role | CHEBI:48422 | angiostatic agents |
CHEBI has role | CHEBI:50846 | biomodulator |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Multiple myeloma | indication | 109989006 | DOID:9538 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.84 | acidic |
pKa2 | 1.86 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 20, 2023 | ADDITIONULLL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 20, 2023 | ADDITIONULLL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 20, 2023 | ADDITIONULLL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 20, 2023 | ADDITIONULLL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 20, 2024 | PEDIATRIC EXCLUSIVITY |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 20, 2024 | PEDIATRIC EXCLUSIVITY |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 20, 2024 | PEDIATRIC EXCLUSIVITY |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 20, 2024 | PEDIATRIC EXCLUSIVITY |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 14, 2027 | PEDIATRIC EXCLUSIVITY |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 14, 2027 | PEDIATRIC EXCLUSIVITY |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 14, 2027 | PEDIATRIC EXCLUSIVITY |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 14, 2027 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Protein cereblon | Cytosolic other | MODULATOR | EC50 | 6.58 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
ID | Source |
---|---|
D08976 | KEGG_DRUG |
4032092 | VANDF |
C2347625 | UMLSCUI |
CHEBI:72690 | CHEBI |
134780 | PUBCHEM_CID |
CHEMBL43452 | ChEMBL_ID |
DB08910 | DRUGBANK_ID |
C467566 | MESH_SUPPLEMENTAL_RECORD_UI |
7348 | IUPHAR_LIGAND_ID |
8873 | INN_ID |
D2UX06XLB5 | UNII |
1369713 | RXNORM |
199372 | MMSL |
29234 | MMSL |
d08041 | MMSL |
014897 | NDDF |
703789000 | SNOMEDCT_US |
703790009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-501 | CAPSULE | 1 mg | ORAL | NDA | 35 sections |
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-502 | CAPSULE | 2 mg | ORAL | NDA | 35 sections |
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-503 | CAPSULE | 3 mg | ORAL | NDA | 35 sections |
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-504 | CAPSULE | 4 mg | ORAL | NDA | 35 sections |